Article

Experimental photodynamic therapy for malignant pleural mesothelioma with pegylated mTHPC

  1. Thorsten Krueger MD1,*,
  2. Hans J. Altermatt MD3,
  3. Daniel Mettler VD4,
  4. Beatrix Scholl MD1,
  5. Lennart Magnusson MD2,
  6. Hans-Beat Ris MD1

Article first published online: 3 JAN 2003

DOI: 10.1002/lsm.10113

Issue

Lasers in Surgery and Medicine

Lasers in Surgery and Medicine

Volume 32, Issue 1, pages 61–68, January 2003

Additional Information

How to Cite

Krueger, T., Altermatt, H. J., Mettler, D., Scholl, B., Magnusson, L. and Ris, H.-B. (2003), Experimental photodynamic therapy for malignant pleural mesothelioma with pegylated mTHPC. Lasers in Surgery and Medicine, 32: 61–68. doi: 10.1002/lsm.10113

Author Information

  1. 1

    Department of Surgery, University Hospital of Lausanne, CH-1011 Lausanne

  2. 2

    Department of Anesthesiology, University Hospital of Lausanne, CH-1011 Lausanne

  3. 3

    Institute of Pathology, Länggasse, Bern, CH-3010 Bern, Switzerland

  4. 4

    Division for Surgical Research, University of Bern, CH-3010 Bern, Switzerland

*Department of Surgery, University Hospital of Lausanne, CH 1011 Lausanne, Switzerland.

Publication History

  1. Issue published online: 3 JAN 2003
  2. Article first published online: 3 JAN 2003
  3. Manuscript Accepted: 5 AUG 2002

Funded by

  • Swiss National Science Foundation. Grant Numbers: 32.32547.91, 32.55818.98

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (138K)

Keywords:

  • mTHPC foscan;
  • dosimetry;
  • nude mice;
  • pleural mesothelioma;
  • neoplasm;
  • pegylation;
  • photodynamic therapy;
  • pleura;
  • pneumonectomy;
  • swine;
  • thorax;
  • xenograft

Abstract

Background and Objectives

Experimental assessment of photodynamic therapy (PDT) for malignant pleural mesothelioma using a polyethylene glycol conjugate of meta-tetrahydroxyphenylchlorin (PEG–mTHPC).

Study Design/Materials and Methods

(a) PDT was tested on H-meso-1 xenografts (652 nm laser light; fluence 10 J/cm2; 0.93, 9.3, or 27.8 mg/kg of PEG–mTHPC; drug-light intervals 3–8 days). (b) Intraoperative PDT with similar treatment conditions was performed in the chest cavity of minipigs (n = 18) following extrapleural pneumonectomy (EPP) using an optical integrating balloon device combined with in situ light dosimetry.

Results

(a) PDT using PEG–mTHPC resulted in larger extent of tumor necrosis than in untreated tumors (P ≤ 0.01) without causing damage to normal tissue. (b) Intraoperative PDT following EPP was well tolerated in 17 of 18 animals. Mean fluence and fluence rates measured at four sites of the chest cavity ranged from 10.2 ± 0.2 to 13.2 ± 2.3 J/cm2 and 5.5 ± 1.2 to 7.9 ± 1.7 mW/cm2 (mean ± SD). Histology 3 months after light delivery revealed no PDT related tissue injury in all but one animal.

Conclusions

PEG–mTHPC mediated PDT showed selective destruction of mesothelioma xenografts without causing damage to intrathoracic organs in pigs at similar treatment conditions. The light delivery system afforded regular light distribution to different parts of the chest cavity. Lasers Surg. Med. 32:61–68,2003. © 2003 Wiley-Liss, Inc.

Get PDF (138K)